Back

Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Chronic heart failure – Pathophysiology and mechanisms Cardiotoxicity of Drugs and Other Therapies ESC Premium Access ESC Congress 2018

About the speaker

Photo
Assistant Professor Sungsoo Cho

Yonsei University, Seoul (Korea (Republic of))

11 More presentations in this session

Presentation thumbnail
Cell growth, survival, and differentiation signal transduction pathways in advanced failing myocardium (gender dependent differences).
Professor P. Leszek (Warsaw, PL)
Abstract Slides
Presentation thumbnail
Accumulating evidence for deleterious effects of digoxin in heart failure and atrial fibrillation: an updated meta-analysis
Associate Professor M. Vamos (Szeged, HU)
Abstract Slides
Presentation thumbnail
Effect of cardiovascular risk factors on left ventricular ejection fraction in HER2 positive breast cancer patients who were treated in adjuvant setting with trastuzumab
Professor M. Deljanin Ilic (Niska Banja, RS)
Abstract Slides
Presentation thumbnail
Therapeutic validity and effectiveness of guideline-recommended medical therapy in acute heart failure patients on regular hemodialysis
Doctor K. Mizobuchi (Tokyo, JP)
Abstract
Presentation thumbnail
Sympathomimetic beta-1AR autoantibodies in patients after heart transplantation are associated with higher mitochondrial coupling efficiency
Doctor J. Haschemi (Duesseldorf, DE)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 3 - Chronic heart failure – Pathophysiology and mechanisms

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Session
Chronic kidney disease and heart failure
thumbnail
Congress Presentation
Moving beyond diuretics: advances in treatment of cardiomyopathies and heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources